Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion type Assertion NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_head.
- NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion description "[Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_provenance.
- NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion evidence source_evidence_literature NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_provenance.
- NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion SIO_000772 16341239 NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_provenance.
- NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion wasDerivedFrom befree-2016 NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_provenance.
- NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_assertion wasGeneratedBy ECO_0000203 NP526341.RAssEneY5OQV9oO3MO0iQvBoJvZUA2_bDoCEscnhfC2E4130_provenance.